about SR One
 
SR One invests globally in emerging biotech companies that are focused on drug discovery, development or delivery and have the potential to make products that can have a dramatic benefit to patients. We are interested in companies with products that are in preclinical development through clinical proof-of-concept. Overall, we look for investments that can provide attractive financial returns and significant strategic value.

 
We have a Team of seven investment professionals that serve as the Fund’s managers and Investment Committee. We understand the challenges facing emerging companies. Together, we bring practical industry expertise, an operational orientation and long-term perspective, from the beginning of the investment process through all aspects of value creation. Our investment record and focus on returns aligns us with financial investors and our industry perspective positions us to work effectively with company management teams.

How We Work
 
We lead investments and work with other financial or strategic investors to syndicate our deals. We will also actively participate in opportunities as part of a syndicate. We are aligned with other financial investors and do not ask for specific product rights or options. We are active investors and typically take board of directors or board observer seats. We also maintain a strict firewall with GlaxoSmithKline (GSK) on confidential items received from a portfolio company or an investment opportunity under review by our team.

Our Fund
 
SR One is structured as an evergreen fund. We place approximately $25-50MM each year, including follow-on investments in our portfolio companies. We invest between $500K and $5MM in each round of financing.

 
Next